Drug Trial Radar · NCT05662241
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
194
Actual
Start
Jan 9, 2023
Primary completion
Nov 13, 2025
Study completion Feb 15, 2029
Sponsor
- Lead sponsor
- Zenas BioPharma (USA), LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Dec 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to examine the efficacy and safety of obexelimab for the prevention of flare of IgG4-related disease (IgG4-RD)
Conditions
- IgG4 Related Disease
Interventions
ObexelimabDrug
Obexelimab is a monoclonal antibody that co-engages CD19 and FcγRIIb to inhibit B cell activity
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary outcome measureTime frame: Randomization to Week 52
Locations
65 sites in 15 countries. Site status is shown where the registry gives one.
Stanford Medicine
Stanford, California
GI PROS Research - Dedicated Research Facility
Naples, Florida
Emory Univeristy
Atlanta, Georgia
Massachusetts General Hospital
Boston, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
Artus Health Centre
Vancouver, British Columbia, Canada
Center for Clinical Research (Nova Scotia Health)
Halifax, Nova Scotia, Canada
Centre Hospitalier Universitaire de Sherbrooke CHUS
Sherbrooke, Quebec, Canada
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Peking University First Hospital
Beijing, Beijing Municipality, China
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
Wuhai, Hubei, China
Yantai Yuhuangding Hospital
Yantai, Shandong, China
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Shanxi Bethune Hospital
Taiyuan, Shanxi, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Hôpital Beaujon
Paris, France
Hôpital de la Pitié Salpétrière
Paris, France
Haut-Lévèque Hospital Usn Building South Hospital Group
Pessac, Bordeaux, France
Hôpitaux Universitaires de Marseille Timone
Saint-Pierre, Marseille, France
Universitätsklinikum Ulm
Ulm, Germany
LMU Klinikum der Universität München
München, Bavaria, Germany
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Brescia, Italy
Azienda Ospedaliera Universitaria Meyer Istituto di Ricovero e Cura a Carattere Scientifico
Florence, Italy
Ospedale San Raffaele S.r.l. - PPDS
Milan, Italy
University of Verona
Verona, Italy
Ospedale San Giovanni Bosco
Turin, Piedmont, Italy
Kansai Medical University Hospital
Hirakata, Japan
Hiroshima University Hospital
Hiroshima, Japan
St. Marianna University Hospital
Kawasaki, Japan
Tokyo Medical Center Hospital
Meguro City, Japan
Nagaoka Red Cross Hospital
Nagaoka, Japan
Nagasaki University Hospital
Nagasaki, Japan
Kita-Harima Medical Center
Ono, Japan
Tazuke Kofukai Medical Research Institute Kitano Hospital
Osaka, Japan
Sapporo Medical University Hospital
Sapporo, Japan
Fujita Health University Hospital
Shinjuku-Ku, Japan
Hospital of University of Occupational and Environmental Health
Kitakyushu, Fukuoka, Japan
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.